BACKGROUND: Androgens are key regulators of prostate gland maintenance and prostate cancer growth, and androgen deprivation therapy has been the mainstay of treatment for advanced prostate cancer for many years. A long-standing hypothesis has been that inherited variation in the androgen receptor (AR) gene plays a role in prostate cancer initiation. However, studies to date have been inconclusive and often suffered from small sample sizes. OBJECTIVE AND METHODS: We investigated the association of AR sequence variants with circulating sex hormone levels and prostate cancer risk in 6058 prostate cancer cases and 6725 controls of Caucasian origin within the Breast and Prostate Cancer Cohort Consortium. We genotyped a highly polymorphic CAG microsatellite in exon 1 and six haplotype tagging single nucleotide polymorphisms and tested each genetic variant for association with prostate cancer risk and with sex steroid levels. RESULTS: We observed no association between AR genetic variants and prostate cancer risk. However, there was a strong association between longer CAG repeats and higher levels of testosterone (P = 4.73 x 10(-5)) and estradiol (P = 0.0002), although the amount of variance explained was small (0.4 and 0.7%, respectively). CONCLUSIONS: This study is the largest to date investigating AR sequence variants, sex steroid levels, and prostate cancer risk. Although we observed no association between AR sequence variants and prostate cancer risk, our results support earlier findings of a relation between the number of CAG repeats and circulating levels of testosterone and estradiol.
BACKGROUND: Androgens are key regulators of prostate gland maintenance and prostate cancer growth, and androgen deprivation therapy has been the mainstay of treatment for advanced prostate cancer for many years. A long-standing hypothesis has been that inherited variation in the androgen receptor (AR) gene plays a role in prostate cancer initiation. However, studies to date have been inconclusive and often suffered from small sample sizes. OBJECTIVE AND METHODS: We investigated the association of AR sequence variants with circulating sex hormone levels and prostate cancer risk in 6058 prostate cancer cases and 6725 controls of Caucasian origin within the Breast and Prostate Cancer Cohort Consortium. We genotyped a highly polymorphic CAG microsatellite in exon 1 and six haplotype tagging single nucleotide polymorphisms and tested each genetic variant for association with prostate cancer risk and with sex steroid levels. RESULTS: We observed no association between AR genetic variants and prostate cancer risk. However, there was a strong association between longer CAG repeats and higher levels of testosterone (P = 4.73 x 10(-5)) and estradiol (P = 0.0002), although the amount of variance explained was small (0.4 and 0.7%, respectively). CONCLUSIONS: This study is the largest to date investigating AR sequence variants, sex steroid levels, and prostate cancer risk. Although we observed no association between AR sequence variants and prostate cancer risk, our results support earlier findings of a relation between the number of CAG repeats and circulating levels of testosterone and estradiol.
Authors: M Zitzmann; M Brune; B Kornmann; J Gromoll; S von Eckardstein; A von Eckardstein; E Nieschlag Journal: J Clin Endocrinol Metab Date: 2001-10 Impact factor: 5.958
Authors: R B Hayes; D Reding; W Kopp; A F Subar; N Bhat; N Rothman; N Caporaso; R G Ziegler; C C Johnson; J L Weissfeld; R N Hoover; P Hartge; C Palace; J K Gohagan Journal: Control Clin Trials Date: 2000-12
Authors: Edward Giovannucci; Michael Pollak; Yan Liu; Elizabeth A Platz; Noreen Majeed; Eric B Rimm; Walter C Willett Journal: Cancer Epidemiol Biomarkers Prev Date: 2003-02 Impact factor: 4.254
Authors: Eugenia E Calle; Carmen Rodriguez; Eric J Jacobs; M Lyn Almon; Ann Chao; Marjorie L McCullough; Heather S Feigelson; Michael J Thun Journal: Cancer Date: 2002-05-01 Impact factor: 6.860
Authors: T J Hartman; J F Dorgan; K Woodson; J Virtamo; J A Tangrea; O P Heinonen; P R Taylor; M J Barrett; D Albanes Journal: Prostate Date: 2001-01-01 Impact factor: 4.104
Authors: S Dejager; H Bry-Gauillard; E Bruckert; B Eymard; F Salachas; E LeGuern; S Tardieu; R Chadarevian; P Giral; G Turpin Journal: J Clin Endocrinol Metab Date: 2002-08 Impact factor: 5.958
Authors: June M Chan; Meir J Stampfer; Jing Ma; Peter Gann; J Michael Gaziano; Michael Pollak; Edward Giovannucci Journal: J Natl Cancer Inst Date: 2002-07-17 Impact factor: 13.506
Authors: Samuel F Gilbert; Amr S Soliman; Mehdi Karkouri; Meaghen Quinlan-Davidson; Ashley Strahley; Mohab Eissa; Subhojit Dey; Ahmed Hablas; Ibrahim A Seifeldin; Mohamed Ramadan; Noureddine Benjaafar; Kathy Toy; Sofia D Merajver Journal: Breast Dis Date: 2011
Authors: Calen P Ryan; Thomas W McDade; Lee T Gettler; Dan T A Eisenberg; Margarita Rzhetskaya; M Geoffey Hayes; Christopher W Kuzawa Journal: Am J Hum Biol Date: 2016-07-15 Impact factor: 1.937
Authors: Ulla Simanainen; Michele Brogley; Yan Ru Gao; Mark Jimenez; D Tim Harwood; David J Handelsman; Diane M Robins Journal: Mol Cell Endocrinol Date: 2011-06-01 Impact factor: 4.102